MICS: the European picture

Article

Feature includes: statistics providing a true picture of the number of European surgeons practising MICS; interviews with European experts; why you should adopt the technique; product showcase.

Key Points

So has industry satisfied today's cataract surgeon or does research and development still have some way to go? Naturally, there will always be room for improvement and research will continue to deliver innovative products; however, many do believe that surgeons now have the instruments necessary to allow them to offer patients a truly first-class MICS service. But are the surgeons convinced?

Belgian market intelligence firm, Tools for Growth, set about finding the answer. They assessed European surgeons' attitudes towards MICS, in the hope of finding out how the introduction of these new technologies has influenced the way they actually perform cataract surgery today.

By conducting, what we believe to be, the most comprehensive and insightful independent market research survey ever performed,1 we can now present the true picture of European cataract surgery today.

The market intelligence firm questioned 915 surgeons in France (n=180), Germany (n=200), the UK (n=175), Italy (n=180) and Spain (n=180) at 720 sites across Europe, including public hospitals, private hospitals, eye clinics and private practices between January and February 2008. The distribution of surgeons questioned accurately mirrored the current climate, with approximately one-third of surgeons operating within a public hospital.

Not only were surgeons questioned about their current practice styles, but they were also asked to predict what style of surgery they believe they would be performing in two years' time.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.